On Jun. 1, 2021, a first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains had begun at the National Institutes of Health Clinical Center in Bethesda, Maryland.

Healthy participants 18 to 50 years old received either a licensed seasonal influenza vaccine or the experimental vaccine, FluMos-v1. Scientists from NIHﾒs National Institute of Allergy and Infectious Diseases (NIAID) developed FluMos-v1 to stimulate antibodies against multiple influenza virus strains by displaying part of the influenza virus hemagglutinin (HA) protein on self-assembling nanoparticle scaffolds.